Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma

Annals of Allergy, Asthma and Immunology

Volumn 95, Issue 3, 2005, Pages 259-265

  Fardon, Tom C ^a   Lee, Daniel K C ^a   Hodge, Melissa R ^a   Lipworth, Brian J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE PHOSPHATE; ANTIHISTAMINIC AGENT; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CORTICOSTEROID; EOSINOPHIL CATIONIC PROTEIN; FEXOFENADINE; FLUTICASONE PROPIONATE PLUS SALMETEROL; NITRIC OXIDE; PLACEBO;

ADD ON THERAPY; ADULT; AGED; ALLERGIC ASTHMA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; CORTICOSTEROID THERAPY; CROSSOVER PROCEDURE; DISEASE MARKER; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG USE; EOSINOPHILIA; FEMALE; FORCED EXPIRATORY VOLUME; HISTAMINE RELEASE; HUMAN; INFLAMMATION; LUNG FUNCTION; MALE; PRIORITY JOURNAL; PROVOCATION TEST; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 25444463611     PISSN: 10811206     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)61223-9     Document Type: Article

References (37)

1. British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax. 2003;58:i1-i94.
2. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Washington, DC: National Institutes of Health, National Heart, Lung, and Blood Institute; 2002.
3. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med. 1998;157:1S-53S.
4. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? the Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170: 836-844.
5. Donahue JG, Weiss ST, Livingston JM, et al. Inhaled steroids and the risk of hospitalization for asthma. JAMA. 1997;277: 887-891.
6. Suissa S, Ernst P, Benayoun S, et al. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000;343:332-336.
7. Finnerty JP, Holgate ST. Evidence for the roles of histamine and prostaglandins as mediators in exercise-induced asthma: the inhibitory effect of terfenadine and flurbiprofen alone and in combination. Eur Respir J. 1990;3:540-547.
8. Finnerty JP, Wood-Baker R, Thomson H, et al. Role of leukotrienes in exercise-induced asthma: inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. Am Rev Respir Dis. 1992;145:746-749.
9. Patel KR. Terfenadine in exercise induced asthma. BMJ Clin Res Ed. 1984;288:1496-1497.
10. Schleimer RP, Schulman ES, MacGlashan DW Jr, et al. Effects of dexamethasone on mediator release from human lung fragments and purified human lung mast cells. J Clin Invest. 1983; 71:1830-1835.
11. Cohan VL, Undem BJ, Fox CC, et al. Dexamethasone does not inhibit the release of mediators from human mast cells residing in airway, intestine, or skin. Am Rev Respir Dis. 1989;140: 951-954.
12. Djukanovic R, Wilson JW, Britten KM, et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis. 1992;145:669-674.
13. 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol. 1992;90:32-42.
14. Currie GP, Lee DKC, Haggart K, et al. Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am J Respir Crit Care Med. 2003;167: 1132-1238.
15. Lee DKC, Jackson CM, Haggart K, et al. Repeated dosing effects of mediator antagonists in inhaled corticosteroid-treated atopic asthmatic patients. Chest. 2004;125:1372-1377.
16. Brannan JD, Anderson MD, Gomes K, King GG, Chan HK, Seale JP. Fexofenadine decreases sensitivity to and montelukast improves recovery from inhaled mannitol. Am J Respir Crit Care Med. 2001;163:1420-1425.
17. Holgate ST, Finnerty JP. Antihistamines in asthma. J Allergy Clin Immunol. 1989;83:537-547.
18. Wilson AM. Are antihistamines useful in managing asthma? Curr Opin Allergy Clin Immunol. 2002;2:53-59.
19. Arnold R, Rihoux J-P, Konig W. Cetirizine counter-regulates interleukin-8 release from human epithelial cells (A549). Clin Exp Allergy. 1999;29:1681-1691.
20. Ciprandi G, Buscaglia S, Pesce G, et al. Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. J Allergy Clinical Immunol. 1995;95:612-621.
21. Paolieri F, Battifora M, Riccio AM, et al. Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines. Ann Allergy Asthma Immunol. 1998;81: 601-607.
22. Sedgwick JB, Busse WW. Inhibitory effect of cetirizine on cytokine-enhanced in vitro eosinophil survival. Ann Allergy Asthma Immunol. 1997;78:581-585.
23. Busse WW, Middleton E, Storms W, et al. Corticosteroid-sparing effect of azelastine in the management of bronchial asthma. Am J Respir Crit Care Med. 1996;153:122-127.
24. Grant JA, Nicodemus CF, Findlay SR, et al. Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. J Allergy Clin Immunol. 1995;95:923-932.
25. Dijkman JH, Hekking PR, Molkenboer JF, et al. Prophylactic treatment of grass pollen-induced asthma with cetirizine. Clin Exp Allergy. 1990;20:483-490.
26. Spector SL, Nicodemus CF, Corren J, et al. Comparison of the bronchodilatory effects of cetirizine, albuterol, and both together versus placebo in patients with mild-to-moderate asthma. J Allergy Clin Immunol. 1995;96:174-181.
27. Tashkin DP, Brik A, Gong H Jr. Cetirizine inhibition of histamine-induced bronchospasm. Ann Allergy. 1987;59:49-52.
28. Lee DKC, Bates CE, Currie GP, et al. Comparative in vivo bioactivity of modern H(1)-antihistamines on AMP challenge in atopic asthma. J Allergy Clin Immunol. 2003;111:337-341.
29. Currie GP, Haggart K, Lee DKC, et al. Effects of mediator antagonism on mannitol and adenosine monophosphate challenges. Clin Exp Allergy. 2003;33:783-788.
30. American Thoracic Society. Standardization of spirometry: 1994 update. Am J Respir Crit Care Med. 1994;152:1107-1136.
31. Tan KS, McFarlane LC, Lipworth BJ. Loss of normal cyclical β2 adrenoceptor regulation and increased premenstrual responsiveness to adenosine monophosphate in stable female asthmatic patients. Thorax. 1997;52:608-611.
32. Bruce C, Yates DH, Thomas PS. Caffeine decreases exhaled nitric oxide. Thorax. 2002;57:361-363.
33. Inman MD, Hamilton AL, Kerstens HAM, et al. The utility of methacholine airway responsiveness measurements in evaluating anti-asthma drugs. J Allergy Clin Immunol. 1997;101: 342-348.
34. Simons FER. Antihistamines. In: Adkinson NF Jr, Yunginger JW, Busse WW, et al, eds. Middleton's Allergy: Principles and Practice. Philadelphia, PA: Mosby; 2003:834-869.
35. Corren J, Harris AG, Aaronson D, et al. Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma [published correction appears in J Allergy Clin Immunol. 1998;101:792]. J Allergy Clin Immunol. 1997;100:781-788.
36. Aaronson DW. Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma. Ann Allergy Asthma Immunol. 1996;76:440-446.
37. 2-agonists in patients with seasonal allergic rhinitis and asthma. Int Arch Allergy Immunol. 2003; 130:307-313.